Dr Brufsky on the Unique Design of the Allogeneic SV-BR-1-GM Vaccine in Metastatic Breast Cancer

(1:29)

Dr Adam Brufsky: Choosing a Therapy for Breast Cancer Patients

(1:19)

Dr. Brufsky on the Disease-Free Survival of Aromatase Inhibitors for Breast Cancer

(1:4)

Adam Brufsky, MD, PhD, discusses the issue of resistance to HER2-targeted therapy

(2:)

Best of SABCS 2022 News - Adam Brufsky, MD, PhD - Promotional Video

(52)

Adam Brufsky, MD, PhD: Choices of Therapy

(1:10)

Adam Brufsky, MD, PhD, elaborates on the clinical implications of DESTINY-Breast01 from SABCS 2020

(2:29)

Treating Bone Mets with Adam Brufsky, MD, PhD

(56:5)

Video ND Filter K\u0026F Concept / Love it!

(5:9)

Adam Brufsky, MD: COVID-19 and Spike Protein Glycosylation

(12:2)

2020 EMBRACE Metastatic Breast Cancer Virtual Forum Series | Research Update for HER2-Positive MBC

(1:3:19)

Dr. Brufsky on the Ascertainment Bias of COVID-19

(2:14)

Adenovirus COVID-19 Vaccines: The Challenge of Prior AD Immunity

(5:56)

Adam Brufsky, MD - University of Pittsburgh Medical Center

(2:32)

The Main Obstacles Associated With Treating Metastatic Triple-Negative Breast Cancer

(6:22)

Reversing Failure Patterns

(33:57)

New Data and a Review of Bisphosphonate Use in Breast Cancer

(6:44)

Adam Brufsky, MD, PhD, describes the treatment landscape of HER2+ metastatic breast cancer

(2:39)

Exciting Advancements in Triple-Negative Breast Cancer

(4:27)

Dr. Brufsky on Challenges in Breast Cancer

(1:6)

Dr. Brufsky on Adjuvant Bisphosphonates for Patients with Breast Cancer

(30)

Adam Brufsky, MD, PhD: Clinical Trial Data Supporting These Choices

(1:51)

Adam Brufsky, MD, PhD: Expectations of Therapy

(1:4)

Dr Adam Brufsky Discusses Value Coordinates of Breast Cancer Care

(2:12)

Adam Brufsky, MD, PhD, discusses results from the Phase III NALA study presented at SABCS 2020

(1:52)

Adam Brufsky, MD, PhD: Expectations of Therapy in Breast Cancer

(1:7)

Adam Brufsky, MD, PhD: Considerations for Different Therapies in Breast Cancer

(49)

Adam Brufsky, MD, PhD: Choices of Therapy in Breast Cancer

(1:44)

An Overview of Immunotherapy in Breast Cancer - An Interview with Adam Brufsky

(4:5)

Adam Brufsky, MD, PhD, considers the investigation of poziotinib in HER2+ metastatic breast cancer

(3:21)